Division of Biomedical and Life Sciences, School of Science, Navrachana University, Vadodara, Gujarat, 391410, India.
Department of Bio-Sciences and Technology, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, Haryana, India.
Med Oncol. 2024 Oct 14;41(11):283. doi: 10.1007/s12032-024-02517-z.
Cancer remains a significant cause of mortality in the world, with increasing prevalence worldwide. There are numerous treatments ranging from surgery to chemotherapy and radiotherapy, but since cancer is a heterogeneous disease, only few patients possibly respond to treatments. However, it opens a huge space for the advent of targeted therapies such as hormone therapy, immunotherapy, and target-specific drugs. Hormonal therapy using hormone agonists/antagonists or hormone receptor inhibitors-called the next-generation hormonal agents-hits distinct hormonal pathways that are involved in breast, prostate and ovarian cancer. Preliminary results show that through combination of drugs, it is possible that the synergistic effects may actually lead to better survival than with the use of single drugs. With manageable adverse effects, hormonal therapy offers much hope for treatment of this rather challenging malignancy of the hormone-sensitive cancers, especially in combination with other treatments.
癌症仍然是世界上主要的致死原因之一,其发病率在全球范围内呈上升趋势。有许多治疗方法,从手术到化疗和放疗,但由于癌症是一种异质性疾病,只有少数患者可能对治疗有反应。然而,这为靶向治疗的出现开辟了广阔的空间,如激素治疗、免疫治疗和针对特定靶点的药物。使用激素激动剂/拮抗剂或激素受体抑制剂的激素治疗——称为下一代激素药物——针对涉及乳腺癌、前列腺癌和卵巢癌的特定激素途径。初步结果表明,通过药物联合使用,协同作用实际上可能导致比单一药物更好的生存。由于不良反应可控制,激素治疗为治疗这种具有挑战性的激素敏感癌症带来了很大的希望,尤其是与其他治疗方法联合使用时。